NewYork-Presbyterian

2017 Outcomes Report for Oncology

Dear Colleague:

We are pleased to bring you our 2017 Report on Clinical and Scientific Innovations in Oncology. The strength of our oncology programs is derived from the exceptional clinical, scientific, and educational resources made possible by the partnership of NewYork-Presbyterian, Columbia University Irving Medical Center, and Weill Cornell Medicine. At the foundation of these programs are two major cancer centers: the National Cancer Institute-designated Herbert Irving Comprehensive Cancer Center at Columbia and the Sandra and Edward Meyer Cancer Center at Weill Cornell.

These centers are home to preeminent clinicians and scientists whose efforts span virtually every type of cancer with a goal of someday finding a cure. Their progress continues to garner attention, from innovative research in organoids for brain cancer to N-of-1 trials for breast metastases to drug development that is changing the prognosis for patients with challenging lung and hematological cancers.

Our patients benefit from collaborations among medical, radiation, and surgical oncologists who look beyond standard-of-care to the unique molecular characteristics of each patient to formulate a personalized therapeutic plan that optimizes the opportunity for a positive outcome. Our oncology healthcare teams are compassionate and committed to providing cohesive and seamless care that supports patients and their families throughout their journey.

At the writing of this report, we are so pleased to announce an unprecedented gift of $700 million to Columbia University and NewYork-Presbyterian that will support cancer research and patient care. This historic bequest by Florence Irving and her late husband, Herbert Irving, will have a profound impact on all aspects of our work in cancer across multiple clinical and scientific disciplines and ultimately change the landscape of cancer care the world over.

Sincerely,

 

Steven J. Corwin

Steven J. Corwin, MD
President and
Chief Executive Officer

NewYork-Presbyterian

Lee Goldman

Lee Goldman, MD
Executive Vice President,
Dean of the Faculties of Health Sciences and Medicine,
and Chief Executive

Columbia University Medical Center

Augustine M.K. Choi

Augustine M.K. Choi, MD
Stephen and Suzanne Weiss Dean
Weill Cornell Medicine


Dear Colleague:

There is great excitement in the field of oncology today. Scientific discoveries and new therapies are helping a greater number of patients with advanced disease. At NewYork-Presbyterian, Columbia University Irving Medical Center, and Weill Cornell Medicine, our clinicians and scientists continue to reveal the underlying mechanisms of cancer development that may ultimately inform the newest generation of therapeutics. At the same time, many challenges continue to confront us the more we delve deeper into the vast complexities of hematological and solid tumor cancers.

In our 2017 Report on Clinical and Scientific Innovations in Oncology, we highlight recent advances and novel initiatives that we believe are bringing us closer to offering therapies that benefit a broader range of patients. These include our work in patient-derived organoids, combination therapies, and new models of care.

The efforts of our faculty are bolstered with funding by major grants from the National Institutes of Health and other organizations and the support of individuals who place their confidence in the promise of our endeavors. This includes, most recently, the awarding of a SPORE grant in prostate cancer and an extraordinary bequest from Florence Irving and her late husband, Herbert Irving.

We are proud of our high-caliber clinical and scientific faculty and grateful for the resources and facilities that enable them to continue to pursue their groundbreaking efforts on behalf of patients and families facing a cancer diagnosis.

Sincerely,

 

Cory Abate-Shen

Cory Abate-Shen, PhD
Interim Director
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/
Columbia University Medical Center

Lewis C. Cantley

Lewis C. Cantley, PhD
Meyer Director, Sandra and Edward Meyer
Cancer Center at Weill Cornell Medicine/
Ronald P. Stanton Clinical Cancer Program at NewYork-Presbyterian

Gary K. Schwartz

Gary K. Schwartz, MD
Chief, Hematology and Oncology
Deputy Director
Weill Cornell Medical Center
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/ Columbia University Medical Center

David M. Nanus

David M. Nanus, MD
Chief, Hematology and Medical Oncology
NewYork-Presbyterian/Weill Cornell Medical Center
Associate Director for Clinical Services
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine/Ronald P. Stanton
Clinical Cancer Program at NewYork-Presbyterian